Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders. Our initial focus is on adults and adolescents who have been diagnosed with ADHD. Adlon is a subsidiary of Purdue Pharma L.P.

The U.S. Food and Drug Administration (FDA) recently approved Adhansia XR™ (methylphenidate hydrochloride) extended-release capsules CII. Read our Press Release.


CNS stimulants, including ADHANSIA XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

The introduction of Adhansia XR will be accompanied by information on safe prescribing practices for this medication and initiatives to support the responsible use, storage, and disposal of all medications in this class.

Considerations for Use of Prescription Stimulants →

Ethics and Compliance

Our Ethics and Compliance Program is a key component of our commitment to the highest standards of pharmaceutical corporate responsibility. More information


Main: 888-827-0618 or

Medical Information: 888-827-0618 and select option 1

To report adverse events from a Purdue product:

  • Call Drug Safety & Pharmacovigilance: 888-726-7535 and select option 2
  • Report a side effect from a Purdue product

For Wholesalers, Distributors & Pharmacies
For information on order placement, returns and credits, or product availability:

To report any suspected violations of ethics, law, or Purdue policy:

  • Call the Ethics & Compliance Hotline: 877‑PURDUE1 (877‑787‑3831) toll‑free, 24 hours a day
  • Callers may choose to remain anonymous and will be protected from retaliation in any form

Media Contact: